Merck

Last updated January 31, 2026

124

Innovation Areas

5,362

Inventors

Collaborations

Plasmepsin x imidazole inhibitors: MerckRecent Research Landscape

Parasitic resistance to monotherapy increases treatment failure rates and clinical costs. These innovations engineer specific heterocyclic chemical combinations to bypass metabolic bypass mechanisms in resistant strains.

What technical problems is Merck addressing in Plasmepsin x imidazole inhibitors?

Parasite egress and invasion failure

(6)evidences

Parasite adaptation renders existing monotherapies ineffective. Synergistic combinations bypass established resistance mechanisms to restore treatment efficacy.